Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, describes the role of liquid biopsy in early breast cancer, particularly in patients at increased risk of recurrence. While not recommended outside clinical trials, findings from such studies may prompt consideration of approved treatment options. Ribociclib can also be reconsidered within regulatory guidelines, and ongoing interventional studies are emphasized as the optimal approach for guiding clinical decisions, ensuring evidence-based treatment strategies in this evolving field. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.